1)      

An impaired DNA repair might be involved in the aetiology of breast cancer.    

(Published in 1986) 

2)

The first-degree relatives of cancer patients have an increased incidence of defective 

DNA repair. 

(Published in 1987)   

(Published in 1988)

3)

Chemo/radiotherapy influences the DNA repair of cancer patients negatively shortly

after treatment and 3-5 years after the end of  treatment, leading to an increased

risk of a secondary tumour.  

(Published in 1992)

1)      

IL-16 is involved in cancer diseases and correlates with the progression.

The  results indicate that there is an increase of Interleukin-16 in sera during tumour progression due to an alteration in the function of the immunocompetent cells.

(Published in 2001)

2)

The simultaneous measurement of IL-6, sIL-6R and sgp130 in sera of tumour patients

patients is an important factor and necessary in evaluating the biological effect

of IL-6 in malignant diseases. 

(Published  in 2001)

3)

The serum values of sgp130 in cancer patients are elevated in all tumour stages.

There are a correlation between the values of sgp130 and sIL-6R in all tumour stages.

(Published in 2001)

4)

There are a significant correlation between the serum values of sICAM-1 and

sgp130 in cancer patients with progression. 

(Published in 2005)

5)

IL-6 downregulates the membrane expression of gp130 in three multiple myeloma

cell lines (OPM-2, RPMI-8226, U-266), although the proliferation of the myeloma

cells increases. 

(Published in 2003) 

(Published in 2006)

6)

There are a relationship between the cytostatic (inhibition of proliferation) and the 

cytocidal (killing of cells) effects of substances in multiple myeloma cell lines: Firstly

the proliferation of tumour cells is inhibited and then afterwards these cells

die by apoptosis or necrosis. 

(Published in 2006) 

(Published in 2008)

7)     

IL-6 has a more marked effect on the proliferation of multiple myeloma cells with

lower proliferation than on those with higher. 

(Published in 2006) 

8)

Viscum album extract (VAQuFrF) inhibits the proliferation of several human multiple myeloma cell lines. The profile of its antitumour effect is identical to that of Vincristine.

(Published in 2010)

9)

Interleukin-6 leads to a marked production of Interleukin-10 in several human multiple myeloma cell lines. Interleukin-10 is an Interleukin-6 related growth factor for multiple myeloma cells.

(Published in 2010)